PRELUDE THERAPEUTICS INC Capital Expenditures
PRELUDE THERAPEUTICS INC (PRLD) reported Capital Expenditures of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC payments to acquire property, plant, and equipment for fiscal 2025 was $67.00K, a 91.23% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC payments to acquire property, plant, and equipment for fiscal 2024 was $764.00K, a 78.25% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC payments to acquire property, plant, and equipment for fiscal 2023 was $3.51M, a 16.36% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC payments to acquire property, plant, and equipment for fiscal 2022 was $3.02M, a 29.96% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $20.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $20.00K derived: sum of 3 quarters · filed 2026-08-11 | $67.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $20.00K derived: sum of 2 quarters · filed 2026-08-11 | $67.00K 10-Q · filed 2025-11-12 | $120.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $67.00K 10-Q · filed 2026-08-11 | $120.00K derived: sum of 3 quarters · filed 2026-08-11 | $183.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $47.00K 10-Q · filed 2026-05-12 | $100.00K derived: sum of 2 quarters · filed 2026-05-12 | $163.00K derived: sum of 3 quarters · filed 2026-05-12 | $522.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $116.00K derived: sum of 2 quarters · filed 2026-03-10 | $475.00K derived: sum of 3 quarters · filed 2026-03-10 | $764.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $422.00K derived: sum of 2 quarters · filed 2025-11-12 | $711.00K 10-Q · filed 2025-11-12 | $1.84M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $359.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $648.00K 10-Q · filed 2025-08-14 | $1.78M derived: sum of 3 quarters · filed 2025-08-14 | $2.37M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $289.00K 10-Q · filed 2025-05-06 | $1.42M derived: sum of 2 quarters · filed 2025-05-06 | $2.01M derived: sum of 3 quarters · filed 2025-05-06 | $2.99M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.72M derived: sum of 2 quarters · filed 2025-03-10 | $2.70M derived: sum of 3 quarters · filed 2025-03-10 | $3.51M 10-K · filed 2025-03-10 |
| 2023-09-30 | $591.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.57M derived: sum of 2 quarters · filed 2024-11-06 | $2.38M 10-Q · filed 2024-11-06 | $2.78M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $983.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.79M 10-Q · filed 2024-08-12 | $2.19M derived: sum of 3 quarters · filed 2024-08-12 | $3.10M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $810.00K 10-Q · filed 2024-05-07 | $1.20M derived: sum of 2 quarters · filed 2024-05-07 | $2.12M derived: sum of 3 quarters · filed 2024-05-07 | $2.88M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $393.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.31M derived: sum of 2 quarters · filed 2024-02-15 | $2.07M derived: sum of 3 quarters · filed 2024-02-15 | $3.02M 10-K · filed 2024-02-15 |
| 2022-09-30 | $916.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $1.67M derived: sum of 2 quarters · filed 2023-11-01 | $2.63M 10-Q · filed 2023-11-01 | $2.92M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $758.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.71M 10-Q · filed 2023-08-03 | $2.01M derived: sum of 3 quarters · filed 2023-08-03 | $2.67M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $952.00K 10-Q · filed 2023-05-08 | $1.25M derived: sum of 2 quarters · filed 2023-05-08 | $1.91M derived: sum of 3 quarters · filed 2023-05-08 | $2.29M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $956.00K derived: sum of 2 quarters · filed 2023-03-15 | $1.34M derived: sum of 3 quarters · filed 2023-03-15 | $2.32M 10-K · filed 2023-03-15 |
| 2021-09-30 | $659.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.04M derived: sum of 2 quarters · filed 2022-11-14 | $2.03M 10-Q · filed 2022-11-14 | $2.35M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $381.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.37M 10-Q · filed 2022-08-09 | $1.70M derived: sum of 3 quarters · filed 2022-08-09 | $1.87M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $986.00K 10-Q · filed 2022-05-10 | $1.31M derived: sum of 2 quarters · filed 2022-05-10 | $1.49M derived: sum of 3 quarters · filed 2022-05-10 | $1.53M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $329.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $499.00K derived: sum of 2 quarters · filed 2022-03-17 | $541.00K derived: sum of 3 quarters · filed 2022-03-17 | $621.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $212.00K derived: sum of 2 quarters · filed 2021-11-12 | $292.00K 10-Q · filed 2021-11-12 | $491.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $122.00K 10-Q · filed 2021-08-12 | $321.00K derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $80.00K 10-Q · filed 2021-05-11 | $279.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $780.00K 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $581.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |